@misc{indiciae2b6f26c9fe4f,
  title = {CXCR2 inhibition enables NASH-HCC immunotherapy},
  author = {Leslie, J. and Mackey, J. B. G. and Jamieson, T. and Ramon-Gil, E. and Drake, T. M. and Fercoq, F. and Clark, W. and Gilroy, K. and Hedley, A. and Nixon, C. and Luli, S. and Laszczewska, M. and Pinyol, R. and Esteban-Fabro, R. and Willoughby, C. E. and Haber, P. K. and Andreu-Oller, C. and Rahbari, M. and Fan, C. and Pfister, D. and Raman, S. and Wilson, N. and Muller, M. and Collins, A. and Geh, D. and Fuller, A. and McDonald, D. and Hulme, G. and Filby, A. and Cortes-Lavaud, X. and Mohamed, N.-E. and Ford, C. A. and Raffo Iraolagoitia, X. L. and MacFalane, A. J. and McCain, M. and Ridgeway, R. and Roberts, E. W. and Barry, S. T. and Graham, G. J. and Heikenwalder, M. and Reeves, H. L. and Llovet, J. M. and Carlin,},
  year = {2022},
  doi = {10.1101/2022.02.24.481779},
  url = {https://www.biorxiv.org/content/10.1101/2022.02.24.481779v1},
  note = {Source identifier: 10.1101/2022.02.24.481779}
}